Cardiovascular · Small molecule (oral, once daily)

Obicetrapib (Ubeslo, Evlarco)

Obicetrapib is an oral CETP inhibitor that lowers LDL cholesterol. It received European Commission approval in September 2026. Its cardiovascular outcomes trial, PREVAIL, will determine whether it succeeds where earlier drugs in its class failed.

Approved outside the U.S.Approved in the EU in 2026 for high cholesterol; no FDA approval; 9,541-patient outcomes trial ongoing

Approved outside the U.S.: Approved by a regulator outside the United States, such as the European Commission, but not by the FDA. About status badges

FDA: Not approved. No approved application appears in openFDA as of Nov 19, 2026 (openFDA lists approved applications only, so a pending submission would not appear). In the United States, this drug is investigational.

DeveloperNewAmsterdam Pharma (partners: Menarini Group (Europe)) · NewAmsterdam Pharma pipeline
Drug typeSmall molecule (oral, once daily)
TargetCholesteryl ester transfer protein (CETP)
MechanismInhibits cholesteryl ester transfer protein (CETP), lowering LDL cholesterol
Other namesTA-8995

Key points

  • Obicetrapib is a once-daily pill that blocks CETP, a protein that moves cholesterol between lipoprotein particles.
  • In the 2,530-patient Phase 3 BROADWAY trial, it lowered LDL cholesterol by 29.9% at 84 days, compared with a 2.7% rise with placebo, in patients already on maximum tolerated lipid-lowering therapy.
  • The European Commission approved obicetrapib alone (Ubeslo) and with ezetimibe (Evlarco) in September 2026, according to the company. openFDA lists no U.S. application record.
  • Earlier CETP inhibitors had a troubled history: torcetrapib increased deaths, dalcetrapib and evacetrapib showed no benefit, and anacetrapib produced a modest 9% reduction in major coronary events.
  • PREVAIL, a 9,541-patient cardiovascular outcomes trial, is the key test. The registry lists an estimated primary completion of November 2026.

Development programs

Each disease a drug is tested for is a separate program, with its own evidence and its own odds.

IndicationStageRegistered trialsHistorical benchmark
Hypercholesterolemia and atherosclerotic cardiovascular disease
LDL-lowering trials are complete. The PREVAIL outcomes trial is active, not recruiting (registry). EU approval is company-reported.
Phase 3 (EU-approved; not FDA-approved)19
5 active · 13 completed
52.4% eventual approval
Phase 3 → application: 57.8%
Alzheimer's disease
An early open-label study is complete. A 400-participant Phase 2 trial (SPINOZA) is recruiting (registry).
Phase 22
1 active · 1 completed
15.1% eventual approval
Phase 2 → Phase 3: 28.9%

Historical benchmarks are industry-wide averages for programs at the same stage, 2011–2020 (BIO, Informa, QLS; eventual-approval figures are from the report’s likelihood-of-approval table, Figure 5b). They are not predictions for this drug. We use all-indication rates because the source does not define which conditions fall in each disease area; see the therapeutic area pages for area-level rates. Benchmarks are withheld where they would mislead, for example after approval or after a failed pivotal trial. See our methodology.

What obicetrapib is

Obicetrapib is an oral, once-daily CETP inhibitor. Cholesteryl ester transfer protein (CETP) moves cholesterol between lipoprotein particles in the blood. Blocking it raises HDL ("good") cholesterol and lowers LDL ("bad") cholesterol and apolipoprotein B. Obicetrapib is developed by NewAmsterdam Pharma, with Menarini as its partner in Europe. It is also available in Europe as a fixed-dose combination with ezetimibe, an older cholesterol drug.

A drug class with a difficult history

Obicetrapib cannot be understood without its predecessors. Four earlier CETP inhibitors reached large cardiovascular outcomes trials, and only one produced a benefit:

Drug Outcomes trial result Lesson
Torcetrapib Raised HDL by 72% and lowered LDL by 25%, but increased cardiovascular events (hazard ratio 1.25) and deaths (hazard ratio 1.58) Off-target effects, including higher blood pressure, can outweigh lipid benefits
Dalcetrapib Raised HDL by 31% to 40% with minimal effect on LDL; trial stopped for futility with no reduction in events (hazard ratio 1.04) Raising HDL alone did not help
Evacetrapib Lowered LDL by 31% and raised HDL by 133%, but showed no reduction in events (hazard ratio 1.01); stopped early for futility Large HDL increases did not translate into benefit
Anacetrapib Reduced major coronary events by about 9% (rate ratio 0.91) over a median of 4.1 years A modest benefit, consistent with its effect on non-HDL cholesterol

Sources: Barter et al., NEJM (2007); Schwartz et al., NEJM (2012); Lincoff et al., NEJM (2017); HPS3/TIMI55–REVEAL, NEJM (2017).

The anacetrapib result is the most informative. Its benefit appeared to track the lowering of non-HDL cholesterol rather than the large rise in HDL. That has shifted the rationale for the class: modern CETP inhibitors such as obicetrapib are positioned primarily as LDL-lowering drugs.

Clinical evidence

BROADWAY

BROADWAY enrolled 2,530 patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia who were already on maximum tolerated lipid-lowering therapy, with a mean baseline LDL cholesterol of 98 mg/dL. Published in the New England Journal of Medicine in 2025:

  • LDL cholesterol changed by −29.9% with obicetrapib and +2.7% with placebo at day 84, a difference of −32.6 percentage points.
  • The incidence of adverse events appeared similar between groups.

Other Phase 3 trials

The company reports that BROOKLYN, in heterozygous familial hypercholesterolemia, and TANDEM, testing the ezetimibe combination, also supported the EU approval. It cites LDL reductions of up to 40% for monotherapy and about 50% for the combination versus placebo (company-reported). Detailed results for each trial are on ClinicalTrials.gov, linked in the trial table below.

PREVAIL

PREVAIL is the trial that will decide obicetrapib's long-term place. It enrolled 9,541 patients (registry) and measures major adverse cardiovascular events. The company reports that enrollment was completed in April 2024. The registry lists an estimated primary completion of November 2026.

Scientific perspective

Obicetrapib's case rests on two points. First, it lowers LDL cholesterol meaningfully on top of existing therapy, and LDL lowering by many mechanisms has reduced cardiovascular events in past trials. Second, in BROADWAY the incidence of adverse events appeared similar to placebo. Torcetrapib's harms have been linked to effects beyond CETP inhibition, including higher blood pressure, so long-term safety data from PREVAIL will be watched closely.

The open question is whether CETP inhibition delivers the benefit expected from its LDL lowering, or whether something specific to the class blunts it. Anacetrapib's modest result suggests the benefit is real but proportional to the cholesterol change. PREVAIL will test this with a larger LDL effect.

Development perspective

  • Europe: approved by the European Commission on September 21, 2026, for adults with primary hypercholesterolemia or mixed dyslipidemia (company-reported).
  • United States: openFDA lists no application record. The company's EU approval announcement did not describe U.S. regulatory plans.
  • Key catalyst: PREVAIL. A positive result would strengthen the case for broad use and any U.S. filing. A neutral result would resemble evacetrapib and would likely limit the drug to LDL lowering in patients who cannot reach targets otherwise.
  • Alzheimer's disease: a 400-participant Phase 2 trial is recruiting. This is an early, exploratory program, and it is tracked separately from the cardiovascular program.

Competitive context

Obicetrapib competes with established LDL-lowering options: statins, ezetimibe, PCSK9-targeting antibodies and siRNA, the oral PCSK9 inhibitor enlicitide (FDA-approved in 2026), and bempedoic acid. Its distinguishing features are oral, once-daily dosing and its potential use in combination. A recruiting Phase 3 trial compares it directly with bempedoic acid (registry).

Development timeline

  1. Aug 2013TULIP Phase 2 trial of TA-8995 (later named obicetrapib) begins in patients with mild dyslipidemia. Registry
  2. Dec 15, 2021BROADWAY Phase 3 trial begins. Registry
  3. Feb 7, 2022PREVAIL cardiovascular outcomes trial begins. Registry
  4. May 7, 2025BROADWAY results published: LDL cholesterol −29.9% versus +2.7% with placebo at day 84. Peer-reviewed
  5. Jul 24, 2026EMA's CHMP adopts a positive opinion recommending marketing authorization. Company-reported
  6. Sep 21, 2026European Commission grants marketing authorization for Ubeslo (obicetrapib) and Evlarco (obicetrapib/ezetimibe). Company-reported

What could change the outlook

  • The PREVAIL outcomes result: whether obicetrapib reduces major adverse cardiovascular events. This is the most important pending event for the drug.
  • Whether the size of any event reduction is consistent with its LDL-lowering effect, the pattern seen with anacetrapib.
  • Any U.S. regulatory submission. The company's EU approval release did not describe U.S. plans.
  • Long-term safety in PREVAIL, given the off-target harms that sank torcetrapib.
  • Results of the Alzheimer's disease Phase 2 program, an unusual indication for a lipid drug.

Latest company disclosures

Company press releases (SEC filings and PR Newswire) that mention Obicetrapib. Company-reported, not independently verified.

  1. Pipeline updateCompany-reportedSep 29, 2026

    NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease

    SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood-based biomarkers associated with Alzheimer’s disease, including p-tau 217, and additional cognitive and...

    Source
    SEC Form 8-K · Other events
  2. RegulatoryCompany-reportedSep 21, 2026

    On September 21, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) along with its partner Menarini Group (“Menarini”) announced that the European Commission (“EC”) has granted marketing authorization for Ubeslo...

    ® (obicetrapib 10 mg monotherapy) and Evlarco ® (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination, or “FDC”) for patients with primary hypercholesterolaemia (heterozygous familial (“HeFH”) and non-familial) or mixed dyslipidaemia, marking the first regulatory approval of obicetrapib worldwide.

    Source
    SEC Form 8-K · Other events
  3. Quarterly reportCompany-reportedAug 5, 2026

    NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

    “Our quarterly update is headlined by the positive opinion for Europe from CHMP, recommending the granting of a marketing authorization for Ubeslo and Evlarco, intended for the treatment of primary hypercholesterolemia or mixed dyslipidemia.

    Source
    SEC Form 8-K · Financial results

All Obicetrapib disclosures in Pipeline News

Clinical trials

29 registered trials list Obicetrapib as an intervention, retrieved from ClinicalTrials.gov on Nov 19, 2026. Status, dates, and enrollment are as reported by sponsors to the registry. “Est.” marks anticipated values.

Hypercholesterolemia and atherosclerotic cardiovascular disease

TrialPhaseStatusEnrollmentPrimary completionResults posted
PREVAIL · NCT05202509
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
Phase 3Active, not recruiting9,541Nov 2026 (est.)No
BROADWAY · NCT05142722
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
Phase 3Completed2,530Sep 26, 2024Yes
MEDICI · NCT07614958
Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days
Phase 3Recruiting426 (est.)Jan 2027 (est.)No
TANDEM · NCT06005597
Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
Phase 3Completed407Sep 25, 2024Yes
BROOKLYN · NCT05425745
Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
Phase 3Completed354May 28, 2024Yes
REMBRANDT · NCT06305559
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
Phase 3Active, not recruiting300 (est.)Nov 2027 (est.)No
RUBENS · NCT07219602
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
Phase 3Active, not recruiting300 (est.)Mar 2028 (est.)No
TULIP · NCT01970215
TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)
Phase 2Completed364Jul 2014No
ROSE · NCT04753606
Randomized Study of Obicetrapib as an Adjunct to Statin Therapy
Phase 2Completed120May 24, 2021Yes
ROSE2 · NCT05266586
Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy
Phase 2Completed119Aug 12, 2022Yes
OCEAN · NCT04770389
Randomized Study of Obicetrapib in Combination With Ezetimibe
Phase 2Completed112May 7, 2021Yes
NCT05421078
A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.
Phase 2Completed102Mar 24, 2023Yes
VINCENT · NCT06496243
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
Phase 2Recruiting69 (est.)Nov 2026 (est.)No
6 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT02241759
Study of the Electrocardiographic Effects of TA-8995
Phase 1Completed136Nov 2014No
NCT01878474
Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 With Single, Escalating Doses in Healthy Subjects
Phase 1Completed96Jun 2009No
NCT01879020
Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects
Phase 1Completed61Jun 2010No
NCT02523391
Bioequivalence Study of Capsule and Tablet Formulations of TA-8995
Phase 1Completed26Nov 2015No
NCT05972278
Investigating the Effect of Obicetrapib on Lipoprotein Metabolism
Phase 1Unknown status22Sep 26, 2024 (est.)No
NCT02408055
ADME Study in Healthy Male Subjects With TA-8995
Phase 1Completed6Aug 2015No

Alzheimer's disease

TrialPhaseStatusEnrollmentPrimary completionResults posted
SPINOZA · NCT07794670
Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease
Phase 2Recruiting400 (est.)Sep 2028 (est.)No
NCT05161715
Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease
Phase 2Completed13May 9, 2023Yes

Clinical pharmacology and supporting studies

TrialPhaseStatusEnrollmentPrimary completionResults posted
VERMEER · NCT06982508
Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers
Phase 2Recruiting100 (est.)Sep 2026 (est.)No
NCT02241772
A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)
Phase 1/2Completed42Jan 2015No
6 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT06547359
A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects
Phase 1Completed94Nov 12, 2024No
NCT06081166
A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin
Phase 1Completed74Dec 2, 2023No
NCT06250205
Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib
Phase 1Completed30Apr 25, 2024No
NCT06050291
Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe
Phase 1Completed28Apr 7, 2024No
NCT02124954
A Preliminary Drug Drug Interaction Study With TA-8995
Phase 1Completed18Jul 2014No
NCT06048302
PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function
Phase 1Completed18Mar 12, 2024No

No registry changes detected since tracking began on Nov 19, 2026. Future status, date, and endpoint changes will be logged here.

Sources

  1. Nicholls SJ, et al. Safety and efficacy of obicetrapib in patients at high cardiovascular risk (BROADWAY). New England Journal of Medicine. 2025;393(1):51–61.Peer-reviewed
  2. NewAmsterdam Pharma. NewAmsterdam Pharma and Menarini Group receive European Commission approval for Ubeslo and Evlarco (September 21, 2026).Company-reported
  3. NewAmsterdam Pharma. Positive CHMP opinion for Ubeslo and Evlarco (July 24, 2026).Company-reported
  4. Barter PJ, et al. Effects of torcetrapib in patients at high risk for coronary events. New England Journal of Medicine. 2007;357(21):2109–2122.Peer-reviewed
  5. Schwartz GG, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. New England Journal of Medicine. 2012;367(22):2089–2099.Peer-reviewed
  6. Lincoff AM, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. New England Journal of Medicine. 2017;376(20):1933–1942.Peer-reviewed
  7. HPS3/TIMI55–REVEAL Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease. New England Journal of Medicine. 2017;377(13):1217–1227.Peer-reviewed
  8. ClinicalTrials.gov. PREVAIL (NCT05202509).Registry
  9. BIO, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021).Industry report

This profile is for education and research. It is not medical advice and not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported results are labeled and have not necessarily been peer reviewed. See our editorial standards and disclaimer.